The Macrophage Stimulating Protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression

Current Drug Targets

Volumn 11, Issue 9, 2010, Pages 1157-1168

  Kretschmann, Kelsi L ^a   Eyob, Henok ^a   Buys, Saundra S ^a,b   Welm, Alana L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Breast cancer; Macrophage stimulating protein; Metastasis; MSP; MST1R; Osteolysis; Ron; Therapeutic target

Indexed keywords

MACROPHAGE STIMULATING PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR TYROSINE KINASE RON; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CELL ACTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; METASTASIS; NONHUMAN; OSTEOCLAST; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR CELL; TUMOR MICROENVIRONMENT; WOUND HEALING;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INFLAMMATION; MACROPHAGES; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASMS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 78651294044     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010792006825     Document Type: Article

References (123)

1. Jemal A, Seigel R, Ward E, Hao Y, Xy J, Thun M. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Vicini FA, Goldstein NS, Wallace M, Kestin L. Molecular evidence demonstrating local treatment failure is the source of distant metastases in some patients treated for breast cancer. Int J Radiat Oncol Biol Phys 2008; 71(3): 689-94.
3. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2009; 7(2): 122-92.
4. Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 2009; 9(7): 824-33.
5. Puente J, Lopez-Tarruella S, Ruiz A, et al. Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Res Treat 2010 [Epub ahead of print].
6. Leonard EJ. Biological aspects of macrophage-stimulating protein (MSP) and its receptor. Ciba Found Symp 1997; 212: 183-91; discussion 92-7.
7. Wang MH, Iwama A, Skeel A, Suda T, Leonard EJ. The murine stk gene product, a transmembrane protein tyrosine kinase, is a receptor for macrophage-stimulating protein. Proc Natl Acad Sci USA 1995; 92(9): 3933-7.
8. Wang MH, Julian FM, Breathnach R, et al. Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain. J Biol Chem 1997; 272(27): 16999-7004.
9. Vigna E, Naldini L, Tamagnone L, et al. Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET protooncogene. Cell Mol Biol (Noisy-le-grand) 1994; 40(5): 597-604.
10. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000; 19(27): 3041-9.
11. Danilkovitch-Miagkova A, Leonard EJ. Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors. Histol Histopathol 2001; 16(2): 623-31.
12. Michieli P, Cavassa S, Basilico C, et al. An HGF-MSP chimera disassociates the trophic properties of scatter factors from their proinvasive activity. Nat Biotechnol 2002; 20(5): 488-95.
13. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 1994; 9(1): 49-57.
14. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003; 3(1): 31-40.
15. Feres KJ, Ischenko I, Hayman MJ. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene 2009; 28(2): 279-88.
16. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991; 10(10): 2867-78.
17. Danilkovitch-Miagkova A, Leonard EJ. Anti-apoptotic action of macrophage stimulating protein (MSP). Apoptosis 2001; 6(3): 183-90.
18. O'Toole JM, Rabenau KE, Burns K, et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006; 66(18): 9162-70.
19. Fassetta M, D'Alessandro L, Coltella N, Di Renzo MF, Rasola A. Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis. Cell Signal 2006; 18(11): 1967-76.
20. Cote M, Miller AD, Liu SL. Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence. Biochem Biophys Res Commun 2007; 360(1): 219-25.
21. Pagan R, Sanchez A, Martin I, Llobera M, Fabregat I, Vilaro S. Effects of growth and differentiation factors on the epithelialmesenchymal transition in cultured neonatal rat hepatocytes. J Hepatol 1999; 31(5): 895-904.
22. Broxmeyer HE, Cooper S, Li ZH, et al. Macrophage-stimulating protein, a ligand for the RON receptor protein tyrosine kinase, suppresses myeloid progenitor cell proliferation and synergizes with vascular endothelial cell growth factor and members of the chemokine family. Ann Hematol 1996; 73(1): 1-9.
23. Nanney LB, Skeel A, Luan J, et al. Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury. J Invest Dermatol 1998; 111(4): 573-81.
24. Nikolaidis NM, Gray JK, Gurusamy D, et al. Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production. Shock 2010; 33(2): 197-204.
25. Correll PH, Iwama A, Tondat S, Mayrhofer G, Suda T, Bernstein A. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct 1997; 1(1): 69-83.
26. Lutz MA, Gervais F, Bernstein A, Hattel AL, Correll PH. STK receptor tyrosine kinase regulates susceptibility to infection with Listeria monocytogenes. Infect Immunol 2002; 70(1): 416-8.
27. Morrison AC, Wilson CB, Ray M, Correll PH. Macrophagestimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J Immunol 2004; 172(3): 1825-32.
28. Yoshimura T, Yuhki N, Wang MH, Skeel A, Leonard EJ. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem 1993; 268(21): 15461-8.
29. Wang MH, Dlugosz AA, Sun Y, Suda T, Skeel A, Leonard EJ. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp Cell Res 1996; 226(1): 39-46.
30. Bhatt AS, Welm AL, Farady CJ, Vasquez M, Wilson K, Craik C. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci USA 2007; 104(14): 5771-6.
31. Kawaguchi M, Orikawa H, Baba T, Fukushima T, Kataoka H. Hepatocyte growth factor activator is a serum activator of singlechain precursor macrophage-stimulating protein. FEBS J 2009; 276(13): 3481-90.
32. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005; 11(6): 2222-8.
33. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008; 100: 1-33.
34. Eder JP VWG, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res [Review] 2009; 15(7): 2207-14.
35. Braga E, Senchenko V, Bazov I, et al. Critical tumor-suppressor gene regions on chromosome 3P in major human epithelial malignancies: allelotyping and quantitative real-time PCR. Int J Cancer 2002; 100(5): 534-41.
36. Senchenko VN, Liu J, Loginov W, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 2004; 23(34): 5719-28.
37. Senchenko V, Liu J, Braga E, et al. Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene 2003; 22(19): 2984-92.
38. Welm AL, Sneddon JB, Taylor C, et al. The macrophage stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A 2007; 104(18): 7570-5.
39. Zinser GM, Leonis MA, Toney K, et al. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 2006; 66(24): 11967-74.
40. Jonkers J, Derksen PW. Modeling metastatic breast cancer in mice. J Mammary Gland Biol Neoplasia 2007; 12(2-3): 191-203.
41. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12(3): 954-61.
42. Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009; 31 Pt 2: 2273-89.
43. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z. Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 2003; 10(2): 136-41.
44. Egeblad M, Littlepage LE, Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 2005; 70: 383-8.
45. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-7.
46. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124(2): 263-6.
47. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438(7069): 820-7.
48. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16(2): 91-102.
49. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193(6): 727-40.
50. Wilson CB, Ray M, Lutz M, Sharda D, Xu J, Hankey PA. The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity. J Immunol 2008; 181(4): 2303-10.
51. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18(5): 349-55.
52. Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 2005; 12(4): 273-81.
53. Wang D, Shen Q, Chen YQ, Wang MH. Collaborative activities of macrophage-stimulating protein and transforming growth factor beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 2004; 23(9): 1668-80.
54. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15(6): 489-500.
55. Zhang Y, Kaplan-Lefko PJ, Rex K, et al. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008; 68(16): 6680-7.
56. Waltz SE, Eaton L, Toney-Earley K, et al. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Invest 2001; 108(4): 567-76.
57. Peace BE, Toney-Earley K, Collins MH, Waltz SE. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 2005; 65(4): 1285-93.
58. Iwama A, Wang MH, Yamaguchi N, et al. Terminal differentiation of murine resident peritoneal macrophages is characterized by expression of the STK protein tyrosine kinase, a receptor for macrophage-stimulating protein. Blood 1995; 86(9): 3394-403.
59. Brunelleschi S, Penengo L, Lavagno L, et al. Macrophage stimulating protein (MSP) evokes superoxide anion production by human macrophages of different origin. Br J Pharmacol 2001; 134(6): 1285-95.
60. Suzuki Y, Funakoshi H, Machide M, Matsumoto K, Nakamura T. Regulation of cell migration and cytokine production by HGF-like protein (HLP) / macrophage stimulating protein (MSP) in primary microglia. Biomed Res 2008; 29(2): 77-84.
61. Skeel A, Yoshimura T, Showalter SD, Tanaka S, Appella E, Leonard EJ. Macrophage stimulating protein: purification, partial amino acid sequence, and cellular activity. J Exp Med 1991; 173(5): 1227-34.
62. Lutz MA, Correll PH. Activation of CR3-mediated phagocytosis by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol 3-kinase, and protein kinase C zeta. J Leukoc Biol 2003; 73(6): 802-14.
63. Liu QP, Fruit K, Ward J, Correll PH. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol 1999; 163(12): 6606-13.
64. Morrison AC, Correll PH. Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophagestimulating protein results in the induction of arginase activity in murine peritoneal macrophages. J Immunol 2002; 168(2): 853-60.
65. Gunella G, Bardelli C, Amoruso A, Viano I, Balbo P, Brunelleschi S. Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway. Br J Pharmacol 2006; 148(4): 478-89.
66. Zhou YQ, Chen YQ, Fisher JH, Wang MH. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages. J Biol Chem 2002; 277(41): 38104-10.
67. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004; 9: 283-9.
68. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005; 15(11): 599-607.
69. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8(12): 958-69.
70. Albina JE, Mills CD, Barbul A, et al. Arginine metabolism in wounds. Am J Physiol 1988; 254(4 Pt 1): E459-67.
71. Cowin AJ, Kallincos N, Hatzirodos N, et al. Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats. Cell Tissue Res 2001; 306(2): 239-50.
72. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341(10): 738-46.
73. Santoro MM, Gaudino G, Marchisio PC. The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell 2003; 5(2): 257-71.
74. Bezerra JA, Carrick TL, Degen JL, Witte D, Degen SJ. Biological effects of targeted inactivation of hepatocyte growth factor-like protein in mice. J Clin Invest 1998; 101(5): 1175-83.
75. Lentsch AB, Pathrose P, Kader S, Kuboki S, Collins MH, Waltz SE. The Ron receptor tyrosine kinase regulates acute lung injury and suppresses nuclear factor kappaB activation. Shock 2007; 27(3): 274-80.
76. McDowell SA, Mallakin A, Bachurski CJ, et al. The role of the receptor tyrosine kinase Ron in nickel-induced acute lung injury. Am J Respir Cell Mol Biol 2002; 26(1): 99-104.
77. Mallakin A, Kutcher LW, McDowell SA, et al. Gene expression profiles of Mst1r-deficient mice during nickel-induced acute lung injury. Am J Respir Cell Mol Biol 2006; 34(1): 15-27.
78. Leonis MA, Toney-Earley K, Degen SJ, Waltz SE. Deletion of the Ron receptor tyrosine kinase domain in mice provides protection from endotoxin-induced acute liver failure. Hepatology 2002; 36(5): 1053-60.
79. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4(4): 221-33.
80. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121(11): 2381-6.
81. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9(4): 239-52.
82. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008; 180(4): 2011-7.
83. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4(1): 71-8.
84. Goldberg and Schwertfeger. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010; 11(9): [Epub ahead of print].
85. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004; 64(19): 7022-9.
86. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315(26): 1650-9.
87. Maggiora P, Marchio S, Stella MC, et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998; 16(22): 2927-33.
88. Ni S, Zhao C, Feng GS, Paulson RF, Correll PH. A novel Stat3 binding motif in Gab2 mediates transformation of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to Friend virus infection. Mol Cell Biol 2007; 27(10): 3708-15.
89. Yoo JY, Huso DL, Nathans D, Desiderio S. Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell 2002; 108(3): 331-44.
90. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9(11): 798-809.
91. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11(12): 1314-21.
92. Kurihara N, Tatsumi J, Arai F, Iwama A, Suda T. Macrophagestimulating protein (MSP) and its receptor, RON, stimulate human osteoclast activity but not proliferation: effect of MSP distinct from that of hepatocyte growth factor. Exp Hematol 1998; 26(11): 1080-5.
93. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10(2): 169-80.
94. Coleman R, Gnant M. New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care 2009; 3(3): 213-8.
95. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3(6): 537-49.
96. Wang MH, Cox GW, Yoshimura T, Sheffler LA, Skeel A, Leonard EJ. Macrophage-stimulating protein inhibits induction of nitric oxide production by endotoxin- or cytokine-stimulated mouse macrophages. J Biol Chem 1994; 269(19): 14027-31.
97. Wang MH, Kurtz AL, Chen Y. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 2000; 21(8): 1507-12.
98. Zhou D, Pan G, Zheng C, Zheng J, Yian L, Teng X. Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. BMC Cancer 2008; 8: 353.
99. Bardella C, Costa B, Maggiora P, et al. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 2004; 64(15): 5154-61.
100. Persons DA, Paulson RF, Loyd MR, et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet 1999; 23(2): 159-65.
101. Angeloni D, Danilkovitch-Miagkova A, Ivanova T, Braga E, Zabarovsky E, Lerman MI. Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene 2007; 26(31): 4499-512.
102. List K, Kosa P, Szabo R, et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009; 175(4): 1453-63.
103. Willett CG, Wang MH, Emanuel RL, et al. Macrophagestimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. Am J Respir Cell Mol Biol 1998; 18(4): 489-96.
104. Willett CG, Smith DI, Shridhar V, et al. Differential screening of a human chromosome 3 library identifies hepatocyte growth factorlike/ macrophage-stimulating protein and its receptor in injured lung. Possible implications for neuroendocrine cell survival. J Clin Invest 1997; 99(12): 2979-91.
105. Chen YQ, Zhou YQ, Fisher JH, Wang MH. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene 2002; 21(41): 6382-6.
106. Okino T, Egami H, Ohmachi H, et al. Presence of RON receptor tyrosine kinase and its splicing variant in malignant and nonmalignant human colonic mucosa. Int J Oncol 1999; 15(4): 709-14.
107. Zhou YQ, He C, Chen YQ, Wang D, Wang MH. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003; 22(2): 186-97.
108. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 2000; 261(1): 229-38.
109. Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 2004; 23(52): 8464-74.
110. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, et al. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 2000; 29(2): 147-56.
111. Beckly JB, Hancock L, Geremia A, et al. Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease. Inflamm Bowel Dis 2008; 14(4): 500-7.
112. Goyette P, Lefebvre C, Ng A, et al. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol 2008; 1(2): 131-8.
113. Ahmadi A, Polyak S, Draganov PV. Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J Gastroenterol 2009; 15(1): 61-6.
114. Camp ER, Yang A, Gray MJ, et al. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 2007; 109(6): 1030-9.
115. Thomas RM, Toney K, Fenoglio-Preiser C, et al. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007; 67(13): 6075-82.
116. Cheng HL, Liu HS, Lin YJ, et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005; 92(10): 1906-14.
117. Hsu PY, Liu HS, Cheng HL, et al. Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. J Urol 2006; 176(5): 2262-7.
118. Fracchioli S, Katsaros D, Maggiora P, Di Renzo MF, Massobrio M. [Evaluation of Ron and Met proto-oncogene expression in epithelial ovarian tumors]. Minerva Ginecol 1999; 51(10): 359-64.
119. Ferrandina G, Martinelli E, Petrillo M, et al. Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients. Gynecol Oncol 2008; 111(2): 237-43.
120. Maggiora P, Lorenzato A, Fracchioli S, et al. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 2003; 288(2): 382-9.
121. Eckerich C, Schulte A, Martens T, Zapf S, Westphal M, Lamszus K. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem 2009; 109(4): 969-80.
122. Thobe MN, Gurusamy D, Pathrose P, Waltz SE. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene 2010; 29(2): 214-26.
123. Chen Q, Seol DW, Carr B, Zarnegar R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 1997; 26(1): 59-66.